Spotlight on Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma: European and US Perspectives on the Evolving Standard of Care Bruce Cheson,

Slides:



Advertisements
Similar presentations
Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small.
Advertisements

What is the Optimal Approach to CLL, BR vs. FCR/FR?
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Brown JR et al. Proc ASH 2013;Abstract 523.
Goede V et al. Proc ASCO 2013;Abstract 7004.
New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,
Palumbo A et al. Proc ASH 2012;Abstract 446.
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
Roberts AW et al. Proc ASH 2014;Abstract 325.
Integrazione del profilo clinico-biologico con le nuove opzioni terapeutiche Francesca R Mauro Dipartimento di Biotecnologie Cellulari ed Ematologia Università.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CLL (Percent Responding 9 or 10)
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Alliance/CALGB 50803: A Phase 2 Trial of Lenalidomide plus Rituximab in Patients with Previously Untreated Follicular Lymphoma1 The ‘RELEVANCE’ Trial:
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment- Naïve.
Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) 1 Lenalidomide.
Lessons from the CLL8 study Adapted from Hallek, oral presentation, ASH 2008 FCR is superior to FC in most cytogenetic subgroups with regard to: Response.
Rituximab efficacy in other haematological malignancies Christian Buske.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
1 Nowakowski GS et al. Proc ASH 2012;Abstract 689.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
Kanti R. Rai, MD NSLIJ-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Hematology Highlights 2013 Expert Reviews of the.
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
Ruan J et al. Proc ASH 2013;Abstract 247.
The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.
Dyer MJS et al. Proc ASH 2014;Abstract 1743.
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
1 Flinn I et al. Proc ICML 2013;Abstract 084.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.
What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Rituximab Maintenance After Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma New Findings in Hematology: Independent Conference.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Geisler C et al. Proc ASH 2011;Abstract 290.
Which is the optimal approach: BR or FCR/FR?
Palumbo A et al. Proc ASH 2012;Abstract 200.
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,
New Findings in Hematology: Independent Conference Coverage
WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No
R-CHOP for Frontline Follicular Lymphoma
Ferrajoli A et al. Proc ASH 2010;Abstract 1395.
Jonathan W. Friedberg M.D., M.M.Sc.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Badoux X et al. Proc ASCO 2010;Abstract 6508.
Vitolo U et al. Proc ASH 2011;Abstract 777.
What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,
Fowler NH et al. Proc ASH 2011;Abstract 99.
Salles GA et al. Proc ASCO 2010;Abstract 8004.
What is the best frontline regimen for CLL patients
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Advani RH et al. Proc ASH 2011;Abstract 443.
Presentation transcript:

Spotlight on Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma: European and US Perspectives on the Evolving Standard of Care Bruce Cheson, MD Professor of Medicine, Head of Hematology Georgetown University Hospital The Lombardi Comprehensive Cancer Center Washington, DC Kanti Rai, MD Division of Hematology-Oncology The Long Island Jewish Medical Center New York, NY Mathias Rummel, MD, PhD Head, Department for Hematology and Medical Oncology The Justus-Liebig-University Hospital Giessen, Germany Clemens Wendtner, MD Professor of Medicine, Department of Internal Medicine and Head of Laboratory of Molecular Biology and Immunology of CLL The University Hospital of Cologne, Germany

GCLLSG CLL8 Phase 3 Trial FC vs FCR N = 817 (Age med : 61 yr; Binet stage A: 5%, B: 64%, C: 32%; -17p: 8%) Hallek M, et al. ASH Abstract 535. FC (n = 409) FCR (n = 408) P CR 21.8%44.1%<.001 Median PFS 32.8 mo51.8 mo<.001 OS 79.0%84.1%.01 Median Observation Time = 37.7 months The largest benefit for FCR was observed in Binet stage A and B FCR did not improve the PFS or OS of patients with a del(17p) FCR caused more neutropenia without increasing rate of severe infections

Progress in CLL Therapy F → FC/M → FCR Tam CS, et al. Blood. 2008;112: Historical Comparison From the M.D. Anderson Cancer Center Time, months Overall Survival

FC vs FCR Patients With Rai III/IV CLL Parikh SA, et al. ASCO Abstract Historical Comparison From the M.D. Anderson Cancer Center FC (n = 38) FCR (n = 102) P CR 29%66%.001 Median PFS 36 mo79 mo.000 Median OS 55 mo120 mo.004 Compared with historical patients treated with FC, FCR was associated with significantly improved response rates and survival

GCLLSG Phase 2 Trial in Advanced CLL Bendamustine and Rituximab as First-line Therapy N = 117 (Age med : 64 yr; Binet stage A: 11.1%, B: 41.0%, C: 47.9%) Fischer K, et al. ASH Abstract 205. Median Observation Time = 15.4 months BR ORR 90.9% CR 32.7% PR 55.5% SD 9.1% In patients with unmutated IgV H, ORR = 88.9% In patients with a del(17p), ORR = 42.9% Major side effects (myelosuppression and infections) were infrequent After 18 months, PFS med has not been reached B (90 mg/m² on days 1 and 2) + R (375 mg/m² for the first cycle and 500 mg/m² for subsequent cycles) BR administered every 28 days (6 courses max.)

Bendamustine-R vs R-CHOP (StiL Trial) Randomized Phase 3 Study N = 549 Rummel MJ, et al. ASH Abstract untreated patients randomized R (375 mg/m 2 ; day 1→every 28 days) + CHOP (standard regimen, every 21 days) 6 cycles max. FL=55%, MZL=12%, WM=8%, SLL=4%, MCL=19% Stage IV (77.5%), III (18.6%) Primary Endpoint: PFS

N = 549 (n = 513) Rummel MJ. ASCO 2010/ASH Joint Session. Bendamustine-R vs R-CHOP (StiL Trial) Safety: Final Results Adverse EventB-RR-CHOPP Neutropenia grade 3+4 (%) <.0001 Leukocytopenia grade 3+4 (%) <.0001 Alopecia (%) <.0001 Infectious complications (n) Paresthesia (n)1873<.0001 Stomatitis (n)1647<.0001 Urticaria and rash (n)

B-R (n=260) R-CHOP (n=253) P ORR92.7%91.3%NA CR39.6%30.0%.0262 N = 549 (n = 513) Rummel MJ. ASCO 2010/ASH Joint Session. Bendamustine-R vs R-CHOP (StiL Trial) Efficacy: Final Results B-R has the potential to become a new standard first-line treatment option for patients with FL, MCL, and other indolent lymphoma types PFS

Front-line Choices for Indolent NHL and CLL: FC, CHOP, or Bendamustine? Practicing physicians in the United States and Europe are likely to use more bendamustine in the future.

Front-line Lenalidomide Elderly Patients With CLL N = 60 (Age med : 71 yr; Rai stage III-IV: 30%; -17p or -11q: 33%; unmutated IgV H : 60%) Badoux X, et al. ASCO Abstract ORR 60% CR 8% nPR 8% PR 43% 5 mg orally daily for the first 56 days → titrated ≤ 25 mg/day as tolerated in 5-mg increments Every cycle (28 days)

Front-line Lenalidomide and Rituximab Patients With CLL: Early Report N = 37 (n = 30) (Age med : 62 yr; Rai stage III-IV: 50%; -17p or -11q: 9%; unmutated IgV H : 50%) James DF, et al. ASCO Abstract Lenalidomide started at 2.5 mg/d → 5 mg and 10 mg on day 8, if tolerated (L 21/35 days [cycle 1] → 21/28 days [cycles 2-7]) Rituximab 50 mg/m 2 day 29, 325 mg/m 2 day 31, 375 mg/m 2 day 33 (cycle 1) → 375 mg/m 2 weekly x 4 (cycle 2) and on day 1 (cycles 3-7) Early results of the ongoing study suggest that lenalidomide/rituximab immunotherapy is tolerable

L-R ORR86% CR + CRu79% PR7% SD14% After 6 cycles of therapy, 1 patients with FL achieved CR The grade 3/4 AEs included rash (6 pts), neutropenia (7 pts), myalgia (4 pts), neuropathy (1 pt), infection (1 pt), and fatigue (1 pt), and thrombosis (1 pt) N = 30 (n = 28; age med : 56 yr) Fowler N, et al. ASCO Abstract Lenalidomide + Rituximab Front-line Therapy of Indolent B-Cell NHL

Ofatumumab-FC in Previously Untreated CLL Randomized, 2-Dose, Phase 2 Trial N = 61 (Age med : 56 yr; Rai stage III/IV: 39% [Gr. A], 53% [Gr. B]; -17p: 6% [Gr. A], 20% [Gr. B]; unmutated IgV H : 52% [Gr. A], 30% [Gr. B]) Wierda WG, et al. ASCO Abstract Ofatumumab Group A, 500 mg (n = 31) Group B, 1000 mg (n = 30) ORR 77%73% CR 32%50% O-FC is highly active at both ofatumumab doses investigated AEs were manageable with no unexpected toxicities After 8 months, PFS med has not been reached Ofatumumab (500 mg or 1000 mg)* on day 1 + Fludarabine (25 mg/m 2 IV daily; days 1-3) + Cyclophosphamide (250 mg/m 2 IV daily; days 1-3) Administered every 28 days (6 courses max.) *In both groups, the first dose of ofatumumab was 300 mg

Novel Options for Rituximab-Refractory Patients Another Anti-CD20 mAb Probably Not the Right Solution

O-CHOP in Previously Untreated FL Randomized, 2-Dose, Phase 2 Trial N = 59 (n = 58; age med : 55 yr [Gr. A], 54 yr [Gr. B}; FLIPI score 3-5: 34% [Gr. A], 38% [Gr. B]) Czuczman M, et al. ASCO Abstract Ofatumumab Group A, 1500 mg (n = 29) Group B, 1000 mg (n = 29) ORR90%100% CR + CRu69%55% At median follow-up of 9.7 months, high response rates achieved Effective across all FLIPI risk groups Well tolerated with no unexpected toxicities Ofatumumab (1500 mg or 1000 mg)* on day 1 + Cyclophosphamide (750 mg/m 2 ; day 3) + Doxorubicin (50 mg/m 2 ; day 3) + Vincristine (1.4 mg/m 2 ; day 3) + Prednisolone (100 mg; days 3-7) Administered every 3 weeks (6 courses max.) *In both groups, the first dose of ofatumumab was 300 mg

VBR Preliminary Results ORR84% CR47% PR37% The most common treatment-related AEs were primarily grade 1 and 2 and included nausea (79%), fatigue (65%), diarrhea (57%), and vomiting (44%) Of the 27% pts with treatment-related PN, only 6% had grade 3 (no grade 4) VBR is active in this heavily pretreated, high-risk population and is generally well tolerated N = 63 (≥ 4 doses of R, but no V or B; 39% refractory to R; 35% high FLIPI score) Fowler N, et al. ASH Abstract 933. Phase 2 VERTICAL Study VBR in Patients With Relapsed or Refractory FL V (1.6 mg/m 2 ; days 1, 8, 15, 22) + B (90 mg/m 2 ; days 1, 2) + R (375 mg/m 2 ; days 1, 8, 15, 22, cycle 1; day 1, cycles 2-5) 5 (35 days) cycles max.

N = 1217 Salles GA, et al. ASCO Abstract PRIMA Phase 3 Study Rituximab Maintenance Therapy in Untreated FL 2 years of rituximab maintenance therapy after induction immunochemotherapy in previously untreated FL significantly improves PFS with little additional toxicity

Cross-fertilization between the US and Europe –Europe → US: bendamustine –US → Europe: lenalidomide –Europe: large randomized trials –US: new drug development Strategic planning between European and US investigators –Avoid duplication of studies –Move toward the more efficient development of better treatment regimens –Improve patient outcomes Evolving Standard of Care European and US Perspectives